Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
Pyxis Oncology Inc (PYXS)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/21/2025: PYXS (3-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 176.36% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance 3.0 | Stock Returns Performance 5.0 |
Profits based on simulation | Last Close 01/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 89.20M USD | Price to earnings Ratio - | 1Y Target Price 8.83 |
Price to earnings Ratio - | 1Y Target Price 8.83 | ||
Volume (30-day avg) 928792 | Beta 1.28 | 52 Weeks Range 1.39 - 6.85 | Updated Date 01/21/2025 |
52 Weeks Range 1.39 - 6.85 | Updated Date 01/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -398.68% |
Management Effectiveness
Return on Assets (TTM) -21.06% | Return on Equity (TTM) -39.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -35079407 | Price to Sales(TTM) 5.52 |
Enterprise Value -35079407 | Price to Sales(TTM) 5.52 | ||
Enterprise Value to Revenue 5.08 | Enterprise Value to EBITDA 1.09 | Shares Outstanding 59465700 | Shares Floating 39080282 |
Shares Outstanding 59465700 | Shares Floating 39080282 | ||
Percent Insiders 24.57 | Percent Institutions 56.63 |
AI Summary
Pyxis Oncology Inc.: A Comprehensive Overview
Company Profile:
History and Background:
Founded in 2019, Pyxis Oncology Inc. (PYXS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for cancer. Building on the legacy of its predecessor, PUMA Biotechnology, PYXS leverages its expertise in hematology and oncology to target unmet medical needs.
Core Business Areas:
- Developing targeted therapies: PYXS focuses on developing therapies that target specific pathways and mutations driving tumor growth.
- Oncology pipeline: The company's pipeline comprises two clinical-stage programs: PYX-201, a small molecule MCL1 inhibitor, and PYX-202, a BCL-2 inhibitor.
Leadership and Corporate Structure:
- Management Team: Dr. Wolfram Carius serves as the President and CEO, bringing extensive experience in drug development. The leadership team also boasts expertise in clinical development, finance, and regulatory affairs.
- Board of Directors: The board comprises seasoned professionals with expertise in pharmaceuticals, finance, and law.
Top Products and Market Share:
PYXS currently has no marketed products. Its lead program, PYX-201, is undergoing Phase 1/2a clinical trials for the treatment of MCL and other hematological malignancies.
Market Share Analysis:
While PYX-201 is not yet commercially available, it targets a significant market. The global MCL treatment market is projected to reach $3.7 billion by 2027. PYXS faces competition from established players like AbbVie and Gilead, who hold a significant market share in this space.
Total Addressable Market:
The global oncology drug market is expected to reach $300 billion by 2027. PYXS operates within this vast market, focusing on specific segments like MCL and other hematological malignancies.
Financial Performance:
As a clinical-stage company, PYXS is yet to generate revenue. The company's financial performance primarily reflects its R&D expenses and administrative costs. Recent financial statements indicate a net loss, typical for companies at this stage.
Dividends and Shareholder Returns:
PYXS does not currently pay dividends, as it prioritizes reinvesting profits in research and development. Shareholder returns will depend on the success of its clinical trials and potential commercialization of its drug candidates.
Growth Trajectory:
PYXS's growth trajectory is tied to the progress of its clinical trials and potential regulatory approvals. The company has shown promising early data from PYX-201 trials, which could pave the way for future growth.
Market Dynamics:
The oncology market is highly competitive and constantly evolving. Technological advancements, personalized medicine, and the increasing demand for affordable treatments are key trends shaping the industry. PYXS aims to address these trends with its innovative and targeted therapies.
Competitors:
PYXS's primary competitors in the MCL treatment space include:
- AbbVie (ABBV): Holds a significant market share with its drug Venclexta.
- Gilead Sciences (GILD): Offers another MCL treatment option with Zydelig.
- BeiGene (BGNE): Developing a BCL-2 inhibitor for MCL treatment.
Key Challenges and Opportunities:
Challenges:
- Demonstrating clinical efficacy and safety of PYX-201 and PYX-202.
- Securing regulatory approvals for its drug candidates.
- Competing with established players in the oncology market.
Opportunities:
- Targeting unmet medical needs in MCL and other hematological malignancies.
- Partnering with other pharmaceutical companies for development and commercialization.
- Leveraging technological advancements in drug discovery and development.
Recent Acquisitions:
PYXS has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
Based on an AI-based analysis of PYXS's financials, market position, and future prospects, the company receives a rating of 6 out of 10. This rating reflects the company's promising clinical data, experienced leadership team, and large addressable market. However, it also acknowledges the challenges of clinical development, regulatory approval, and competition.
Sources and Disclaimers:
This analysis utilized information from the following sources:
- PYXS Oncology Inc. website: https://www.pyxis.com/
- Securities and Exchange Commission (SEC) filings: https://www.sec.gov/edgar/searchedgar/companysearch.html
- Market research reports from reputable sources like EvaluatePharma and GlobalData
Disclaimer:
This information is provided for general knowledge and should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.
About Pyxis Oncology Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-08 | CEO, President & Director Dr. Lara S. Sullivan M.D., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 54 | Website https://www.pyxisoncology.com |
Full time employees 54 | Website https://www.pyxisoncology.com |
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.